Tumor cells harboring such mutations exhibit decreased tumor immunogenicity and/or IFNγ insensitivity, leading to evasion of T‐cell‐mediated anti‐tumor immunity and resistance to immunotherapy [4, 7, 8]. Here, IFNG is linked to neoplasm.